Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.
To investigate whether distinct populations have differing human immunodeficiency virus type 1 (HIV) neutralizing antibody responses, we compared 20 women from Tanzania's HIV Superinfection Study (HISIS) cohort, who were infected multiple HIV subtypes, and 22 women from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) cohort, who were infected exclusively with HIV subtype C. By 2 years after infection, 35% of HISIS subjects developed neutralization breadth, compared with 9% of CAPRISA subjects (P = .0131). Cumulative viral loads between 3 and 12 months were higher in the HISIS group (P = .046) and strongly associated with breadth (P < .0001). While viral load was the strongest predictor, other factors may play a role, as the odds of developing breadth remained higher in HISIS even after correction for viral load.
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town.
Gama P
GP
Bandawe
Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services School of Pathology, University of the Witwatersrand, Johannesburg Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Penny L
PL
Moore
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Lise
L
Werner
Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services.
Elin S
ES
Gray
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town.
Daniel J
DJ
Sheward
Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services.
Maphuti
M
Madiga
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town.
Andile
A
Nofemela
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town.
Ruwayhida
R
Thebus
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town.
Jinny C
JC
Marais
NIMR-Mbeya Medical Research Center, Tanzania.
Leonard
L
Maboko
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Salim S
SS
Abdool Karim
Department of Infectious Diseases and Tropical Medicine, Klinikum of Ludwig Maximilians University German Center for Infection Research, Partner Site Munich, Germany.
Michael
M
Hoelscher
Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services School of Pathology, University of the Witwatersrand, Johannesburg Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Lynn
L
Morris
Institute of Infectious Diseases and Molecular Medicine Division of Medical Virology, University of Cape Town National Health Laboratory Services, Cape Town Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
Carolyn
C
Williamson
D057134:Antibodies, Neutralizing / Q000097:blood*; D015331:Cohort Studies; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D006801:Humans; D013019:South Africa / Q000453:epidemiology; D013636:Tanzania / Q000453:epidemiology; D019562:Viral Load
D057134:Antibodies, Neutralizing; D015483:HIV Antibodies
Africa; HIV genetic subtypes; broadly neutralizing antibodies; cohorts; viral load